These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
44. TransMolecular receives FDA approval for 131-I-TM-601 IND application. Expert Rev Anticancer Ther; 2002 Apr; 2(2):139. PubMed ID: 12113233 [No Abstract] [Full Text] [Related]
45. Use of eINDs for evaluation of multiple related PET amyloid plaque imaging agents. Skovronsky D J Nucl Med; 2008 Jun; 49(6):47N-48N. PubMed ID: 18511825 [No Abstract] [Full Text] [Related]
46. Regulation of the compounding of positron emission tomography drugs. Hung JC Am J Health Syst Pharm; 2001 Jan; 58(2):134-9. PubMed ID: 11202536 [TBL] [Abstract][Full Text] [Related]
47. Investigational new drug application; exception from informed consent; technical amendment--FDA. Final rule. Fed Regist; 1997 Jun; 62(115):32479. PubMed ID: 10169828 [TBL] [Abstract][Full Text] [Related]
48. Positron emission tomography imaging of cancer biology: current status and future prospects. Chen K; Chen X Semin Oncol; 2011 Feb; 38(1):70-86. PubMed ID: 21362517 [TBL] [Abstract][Full Text] [Related]
49. Market watch: Value of 2016 FDA drug approvals: reversion to the mean? Schulze U; Ringel M; Panier V; Baedeker M Nat Rev Drug Discov; 2017 Feb; 16(2):78. PubMed ID: 28148943 [No Abstract] [Full Text] [Related]
50. Regulatory science: a special update from the United States Food and Drug Administration: Preclinical issues and status of investigation of botanical drug products in the United States. Wu KM; DeGeorge JG; Atrakchi A; Barry E; Bigger A; Chen C; Du T; Freed L; Geyer H; Goheer A; Jacobs A; Jean D; Rhee H; Osterberg R; Schmidt W; Farrelly JG Toxicol Lett; 2000 Jan; 111(3):199-202. PubMed ID: 10643863 [TBL] [Abstract][Full Text] [Related]
51. The role of exploratory investigational new drugs for translating radiopharmaceuticals into first-in-human studies. Schwarz SW; Oyama R J Nucl Med; 2015 Apr; 56(4):497-500. PubMed ID: 25766895 [TBL] [Abstract][Full Text] [Related]
52. Causality Assessment in Premarketing Drug Clinical Trials: Regulatory Evolution in the USA and Ongoing Concerns. Goldman SA Drug Saf; 2016 Oct; 39(10):895-901. PubMed ID: 27473417 [TBL] [Abstract][Full Text] [Related]
53. FDA cGMP requirements for PET drugs. Norenberg JP; Schwarz S; VanBrocklin H J Nucl Med; 2011 May; 52(5):16N. PubMed ID: 21536923 [No Abstract] [Full Text] [Related]
54. FDA approves treatment IND protocol for taxol. Clin Pharm; 1992 Nov; 11(11):912. PubMed ID: 1361164 [No Abstract] [Full Text] [Related]
55. Expanding Patient Access to Investigational Drugs: Single Patient Investigational New Drug and the "Right to Try". Van Norman GA JACC Basic Transl Sci; 2018 Apr; 3(2):280-293. PubMed ID: 30062214 [TBL] [Abstract][Full Text] [Related]
56. Investigational new drug applications; clinical holds--FDA. Direct final rule. Fed Regist; 1998 Dec; 63(239):68676-8. PubMed ID: 10187558 [TBL] [Abstract][Full Text] [Related]
57. New frontiers in the design and synthesis of imaging probes for PET oncology: current challenges and future directions. Smith G; Carroll L; Aboagye EO Mol Imaging Biol; 2012 Dec; 14(6):653-66. PubMed ID: 22948535 [TBL] [Abstract][Full Text] [Related]
58. Rare cancer trial design: lessons from FDA approvals. Gaddipati H; Liu K; Pariser A; Pazdur R Clin Cancer Res; 2012 Oct; 18(19):5172-8. PubMed ID: 22718862 [TBL] [Abstract][Full Text] [Related]
59. Regulatory and operational challenges in conducting Asian International Academic Trial for expanding the indications of cancer drugs. Hata T; Nakamura K; Yonemori K; Noguchi E; Watanabe M; Sohn J; Lu YS; Yap YS; Tamura K; Fujiwara Y Clin Transl Sci; 2021 May; 14(3):1015-1025. PubMed ID: 33382914 [TBL] [Abstract][Full Text] [Related]